Clinical Trial Update: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of checkpoint inhibitors in men with progressive metastatic castration-resistant prostate cancer characterized by mismatch repair defic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Snippet

Sponsor: VA Office of Research and Development | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING